Unveiling 13 Analyst Insights On Boston Scientific
Portfolio Pulse from Benzinga Insights
In the past three months, 13 analysts have updated their ratings on Boston Scientific (NYSE:BSX), showing a predominantly bullish outlook. The average 12-month price target has been raised to $73.08, indicating a 12.09% increase from the previous target. Analysts from firms like Argus Research, Citigroup, and TD Cowen have raised their price targets, reflecting optimism about the company's future performance. Despite this, Boston Scientific's financial indicators such as ROE and ROA are below industry standards, and its revenue growth, while substantial, lags behind its peers in the Health Care sector.
April 03, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific has received positive analyst ratings with an increased average 12-month price target of $73.08. Financial performance indicators show mixed results, with strong revenue growth but below-average ROE and ROA.
The positive shift in analyst ratings and increased price targets suggest a bullish outlook for Boston Scientific in the short term. However, investors should also consider the company's financial performance indicators, such as below-average ROE and ROA, which could impact long-term growth.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100